Swedish company Epigenica raises $2.2M led by Voima Ventures to expand epigenetic solutions

Epigenica, is a Swedish life sciences technology company in high-throughput epigenetic screening tools and solutions, announced that it has closed a $2.2 million round. The round was led by Voima Ventures with participation from Navigare Ventures, Leksell Social Ventures, and current shareholder Almi Invest. The company shared news with AIN.

About Epigenica 

• Epigenica is a Stockholm-based life sciences tech company, founded in 2020, which advancing high-throughput epigenetic solutions for research, diagnostics, and drug development. Its EpiFinder platform enables simultaneous analysis of multiple epigenetic markers, providing high-resolution, efficient, and affordable results. 

• The platform supports oncology, pharmaceutical development, and longevity applications, using Epigenica’s patented hmqChIP technology. It enables cost-effective epigenomic profiling and accelerates NGS applications, advancing research and improving human health.

Investment details

The round was led by Voima Ventures with participation from Navigare Ventures, Leksell Social Ventures, and current shareholder Almi Invest.

• Voima Ventures, is a Helsinki-based venture capital firm, specializing in deep tech investments across the Nordic and Baltic regions. The firm focuses on science-driven startups in sectors such as life sciences, advanced manufacturing, quantum computing, AI, and sustainable materials.

• The company invested in ArgusEye, Sooma, SemiQon, StemSight, Aisti and Avenue Biosciences.

The funding will accelerate the development of Epigenica’s products, including EpiFinder Genome, Global, and cNUC kits, support service and data infrastructure, and facilitate expansion into the U.S. market.